Aerpio shares tumble as lead eye drug trips up in mid-stage diabetic retinopathy study
Roughly two years after raising $40 million in a private placement, Aerpio Pharmaceuticals’ lead experimental eye drug has hit a roadblock after failing a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
